Sangui Biotech: Preclinical Trials Demonstrate: Sangui Hemoglobin Preparation Improves Oxygen Supply of Vital Organs
November 11 2014 - 9:00AM
Business Wire
A possible success in treating septic shock has now been
attained by the research team embracing SanguiBioTech GmbH, the
Excellence Cluster Cardio Pulmonary System (ECCPS) and TransMIT
Gesellschaft für Technologietransfer mbH. Preclinical trials at
Giessen University underpin that a hemoglobin based product
developed by SanguiBioTech is apt to improve the oxygen supply of
vital organs. It is now being supposed that Sangui's
hemoglobin-based artificial oxygen carriers may interrupt the
self-perpetuating mechanism of septic shock, that has so far been
highly resistant to treatment, and may thus ultimately reduce the
high mortality rates.
A septic shock is the life threatening final phase of a sepsis.
The blood circulation, else exactly tuned to meet the needs of the
body, begins to severely malfunction which results in deficient
oxygen supply of the body tissue. This hypoxia induces a
progressional intoxication of the body with bacteria and bacteria
debris. Modern medical science has not yet identified suitable
therapies to effectively fight this self-perpetuating mechanism of
septicemia, which, therefore, results in mortality rates of 50 to
60 percent.
Preclinical trials in Giessen now demonstrate that an
oxygen-carrying hemoglobin liquid in the abdomen did significantly
improve the oxygen supply to the intestines. This is likely to be a
decisive new therapeutic approach to disrupting this lethal loop.
The preclinical trials are being continued as planned, extending
the scope to additional indications such as ARDS (acute respiratory
distress syndrome) and further hemoglobin preparations as developed
by SanguiBioTech.
Sangui BioTech International, Inc. ("SGBI") is a holding company
the shares of which are being traded on the OTCQB venture stage
marketplace for early stage and developing U.S. and international
companies (OTCQB: SGBI). Companies are current in their reporting
and undergo an annual verification and management certification
process. Sangui shares also trade on the OTC markets of Berlin and
Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to
provide financing and access to the capital markets for the
enterprises of the Sangui group. SanguiBioTech GmbH is a ninety
percent subsidiary of Sangui BioTech International, Inc.
ECCPS is an organization set up jointly by the universities of
Frankfurt and Giessen together with the Max Planck Institute for
Heart and Lung Research in Bad Nauheim. It ranks among the world's
leading organizations of this type. This unique centre for
translational medicine combines innovative medical research in the
field of heart and lung diseases with their practical advancements
based on preclinical and clinical studies. Its aim is to work
together with industry on developing innovative drugs and
substances.
TransMIT Gesellschaft für Technologietransfer mbH
(www.transmit.de) being the unit in charge of technology transfer
at Justus-Liebig University in Giessen is involved in carrying out
this project.
Some of the statements contained in this news release discuss
future expectations, contain projections of results of operation or
financial condition or state other “forward-looking” information.
These statements are subject to known and unknown risks,
uncertainties, and other factors that could cause the actual
results to differ materially from those contemplated by the
statements. The forward-looking information is based on various
factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections
include, among many others, the ability of the Company to raise
sufficient capital to meet operating requirements. Words such as
“anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” and variations of such words and similar expressions
are intended to identify such forward-looking statements. Unless
required by law, the Company undertakes no obligation to update
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.
Sangui BiotechJoachim FleingPhone: +49 (179) 7963472Fax: +49
(2302) 915191e-mail: fleing@sangui.de
Sangui Biotech (CE) (USOTC:SGBI)
Historical Stock Chart
From Jan 2025 to Feb 2025
Sangui Biotech (CE) (USOTC:SGBI)
Historical Stock Chart
From Feb 2024 to Feb 2025